Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?

•Several monoclonal antibodies (mAbs) direct against the Receptor binding domain of the S protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) received an Emergency Use Authorization for outpatient management of mild to moderate manifestation from COVID-19.•The combination of casirivimab and imdevimab or bamlanivimab and etesevimab reduced the hospitalization rate and emergency department admissions in patients with a mild infection, and risk factors for severe manifestation from COVID-19.•A large amount of other monoclonal antibodies is currently under investigation.•Under the pressure of natural immunity and treatment with mAbs, SARS-CoV-2 has the potential to select viral variants with reduced susceptibility to mAbs and vaccines.